Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

被引：47

作者：

Baghaei, Kaveh ^{[1
,2
]}

Mazhari, Sogol ^{[1
]}

Tokhanbigli, Samaneh ^{[1
]}

Parsamanesh, Gilda ^{[1
]}

Alavifard, Helia ^{[1
]}

Schaafsma, Dedmer ^{[3
]}

Ghavami, Saeid ^{[4
,5
,6
,7
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Basic & Mol Epidemiol Gastrointestinal Disorders, Tehran 1985717413, Iran

[2] Shahid Beheshti Univ Med Sci, Res Inst Gastroenterol & Liver Dis, Gastroenterol & Liver Dis Res Ctr, Tehran 1985717413, Iran

[3] Sci Impact, Winnipeg, MB, Canada

[4] Univ Manitoba, Rady Fac Hlth Sci, Max Rady Coll Med, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada

[5] Univ Manitoba, Canc Care Manitoba, Res Inst Oncol & Hematol, Winnipeg, MB R3E 0V9, Canada

[6] Univ Manitoba, Children Hosp Res Inst Manitoba, Biol Breathing Theme, Winnipeg, MB R3E 0V9, Canada

[7] Katowice Sch Technol, Fac Med, PL-40555 Katowice, Poland

来源：

DRUG DISCOVERY TODAY | 2022年 / 27卷 / 04期

关键词：

Liver diseases; Extracellular signaling; Cell phenotype; Fibrogenic myofibroblasts; Autophagy; NF-KAPPA-B; HEDGEHOG SIGNALING INHIBITOR; TGF-BETA; ANTIFIBROTIC ACTIVITY; EXTRACELLULAR-MATRIX; RECEPTOR; AUTOPHAGY; PATHWAY; ANGIOGENESIS; PDGF;

D O I：

10.1016/j.drudis.2021.12.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hepatic fibrosis is a manifestation of different etiologies of liver disease with the involvement of multiple mediators in complex network interactions. Activated hepatic stellate cells (aHSCs) are the central driver of hepatic fibrosis, given their potential to induce connective tissue formation and extracellular matrix (ECM) protein accumulation. Therefore, identifying the cellular and molecular pathways involved in the activation of HSCs is crucial in gaining mechanistic and therapeutic perspectives to more effectively target the disease. In addition to a comprehensive summary of our current understanding of the role of HSCs in liver fibrosis, we also discuss here the proposed therapeutic strategies based on targeting HSCs.

引用

页码：1044 / 1061

页数：18

共 50 条

[41] Dominant-negative soluble PDGF-β receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis
Borkham-Kamphorst, E
Herrmann, J
Stoll, D
Treptau, J
Gressner, AM
Weiskirchen, R
LABORATORY INVESTIGATION, 2004, 84 (06) : 766 - 777
[42] A role for autophagy during hepatic stellate cell activation
Thoen, Lien F. R.
Guimaraes, Eduardo L. M.
Dolle, Laurent
Mannaerts, Inge
Najimi, Mustapha
Sokal, Etienne
van Grunsven, Leo A.
JOURNAL OF HEPATOLOGY, 2011, 55 (06) : 1353 - 1360
[43] Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis
Wang, Fa-Da
Zhou, Jing
Chen, En-Qiang
FRONTIERS IN PHARMACOLOGY, 2022, 13
[44] Catalase ameliorates hepatic fibrosis by inhibition of hepatic stellate cells activation
Dong, Yuwei
Qu, Ying
Xu, Mingyi
Wang, Xingpeng
Lu, Lungen
FRONTIERS IN BIOSCIENCE-LANDMARK, 2014, 19 : 535 - U5541
[45] STAT3 inhibition suppresses hepatic stellate cell fibrogenesis: HJC0123, a potential therapeutic agent for liver fibrosis
Lopez, Omar Nunez
Bohanon, Fredrick J.
Wang, Xiaofu
Ye, Na
Corsello, Tiziana
Rojas-Khalil, Yesenia
Chen, Haijun
Chen, Haiying
Zhou, Jia
Radhakrishnan, Ravi S.
RSC ADVANCES, 2016, 6 (102): : 100652 - 100663
[46] Sauchinone attenuates liver fibrosis and hepatic stellate cell through TGF-β/Smad signaling pathway
Lee, Ju-Hee
Jang, Eun Jeong
Seo, Hye Lim
Ku, Sae Kwang
Lee, Jong Rok
Shin, Soon Shik
Park, Sun-Dong
Kim, Sang Chan
Kim, Young Woo
CHEMICO-BIOLOGICAL INTERACTIONS, 2014, 224 : 58 - 67
[47] Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targeting the TGF-β1/Smad and MAPK signaling pathways
Peng, Yu
Li, Li
Zhang, Xin
Xie, Mingyan
Yang, Congying
Tu, Sha
Shen, Hong
Hu, Gaoyun
Tao, Lijian
Yang, Huixiang
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (01) : 41 - 48
[48] Quiescent hepatic stellate cell activation in liver fibrosis: Have we found the right trigger yet?
Ezhilarasan, Devaraj
Najimi, Mustapha
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
[49] Docosahexaenoic acid inhibits hepatic stellate cell activation to attenuate liver fibrosis in a PPARγ-dependent manner
He, Jianlin
Hong, Bihong
Bian, Mianli
Jin, Huanhuan
Chen, Junde
Shao, Jiangjuan
Zhang, Feng
Zheng, Shizhong
INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 75
[50] Schisandrin B Attenuates Hepatic Stellate Cell Activation and Promotes Apoptosis to Protect against Liver Fibrosis
Li, Zhiman
Zhao, Lijuan
Xia, Yunshi
Chen, Jianbo
Hua, Mei
Sun, Yinshi
MOLECULES, 2021, 26 (22):

← 1 2 3 4 5 →